Recent Updates
Recently added Catalysts
ANTX Positive Sentiment

AN2 Therapeutics to Participate at Upcoming Investor Conferences

Tuesday, October 20, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: AN2 Therapeutics, a clinical stage biopharmaceutical company, announced its participation in three investor conferences in November. CEO Eric Easom will represent the company at the Guggenheim 3rd Annual Healthcare Innovation Conference. This engagement highlights the company's commitment to investor relations and growth.

Market Sentiment Analysis

POSITIVE FACTORS

  • AN2 Therapeutics is actively engaging with investors.
  • Participation in multiple conferences indicates growth potential.
  • Company management will present at notable healthcare events.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+92%
120-day peak, hindsight
Typical move
3.1%
average across 5 past catalysts
Cash runway
~32 mo
Minimal dilution risk
Lead asset
AN2-502998
Phase 1 · Undisclosed

Full Press Release Details

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical stage biopharmaceutical company discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced company management will participate in three upcoming investor conferences in November. Details of the events are as follows: Guggenheim 3rd Annual Healthcare Innovation Conference, November 9-11, 2026 Eric Easom, Co-Founder, Chairman, President and CEO, will

Frequently Asked Questions

What conferences will AN2 Therapeutics attend?

AN2 Therapeutics will participate in three investor conferences in November.

Who will represent AN2 Therapeutics at the conferences?

CEO Eric Easom will represent AN2 Therapeutics at the events.

When is the Guggenheim Healthcare Innovation Conference?

The conference will take place from November 9-11, 2026.

What is AN2 Therapeutics focused on?

The company develops novel small molecule therapeutics from its boron chemistry platform.

ShareAdd on Google
Tags: ANTX AN2 Therapeutics investor conferences biopharmaceuticals healthcare innovation
Last updated: Oct 20, 2026

Biotech snapshot

Cash runway
$80M liquidity · $2M/mo burn
~32 mo
Minimal dilution risk
Lead asset
AN2-502998Phase 1
Undisclosed →

Catalyst track record

+92%
best trade around ANTX's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for ANTX.

See every catalyst's timing & PoA →